FDA Sends Mylan Warning Letter

News
Article

The agency sent a warning letter after an inspection of the company’s Sangareddy District, India found inadequate cleaning procedures.

FDA sent a warning letter to Mylan Laboratories Limited–Unit 7, dated Aug. 20, 2020, after an inspection of the company’s Pashamylaram, Patancheru (M), Sangareddy District, India facility found deviations in current good manufacturing practices (CGMPs) for API. The inspection was conducted from Feb. 24–28, 2020.

According to the letter, the facility did not have cleaning procedures adequate enough to prevent contamination or carry-over of material. Specifically, the company did not have adequate cleaning records for storage tanks. “During the inspection our investigators queried your firm on the quality of recovered solvents held in these storage tanks. Your firm management stated that complete impurity profiles of recovered solvents were not performed during the initial evaluation of your solvent recovery contract manufacturing organizations (CMO). Coupled with inadequate cleaning records, there are limited assurances that your non-dedicated equipment would not contribute to cross-contamination or carry-over of residual impurities,” the letter stated. The agency also stated the company used a CMO that was on Import Alert 66-40 and had received an FDA warning letter.

FDA also stated that the company had an inadequate cleaning validation and verification program for non-dedicated manufacturing and storage equipment. “An inadequate scope of impurity analysis, in combination of non-dedicated equipment, lack of cleaning records, and introduction of elevated unknown impurities, increase the risk potential for API and API intermediate cross-contamination,” the agency stated.

The agency requested the company provide a third-party retrospective assessment of its cleaning effectiveness to determine cross-contamination hazards, improvements to its cleaning validation program, and summary of steps to be taken to update its change management system.

The company was also cited for failing to control and monitor procedures to recover solvents before reuse, including not adequately testing incoming raw materials. FDA requested the company provide a detailed plan for monitoring unknown impurities from fresh solvents, a plan for monitoring process control, procedures for impurity profile analysis, and an updated procedure for evaluating unknown peaks in chromatograms.

FDA stated in the letter that similar CGMP violations were found at another facility in the company’s network. “On November 5, 2019, Mylan Laboratories Limited – Unit 8, FEI No. 3002785310, was issued Warning Letter 320-20-06 for, among other things, failure to have adequate written procedures for receipt, identification, testing, and handling of raw materials and a failure to clean equipment and utensils to prevent contamination or carry-over of material. The poor controls of recovered solvents at this facility led to contamination of drugs with (b)(4) impurities,” the letter stated. “These repeated failures at multiple sites manufacturing API demonstrate that your company’s oversight and control over the manufacture of drugs is inadequate. You should immediately and comprehensively assess your company’s global manufacturing operations to ensure that systems and processes, and ultimately, the products manufactured, conform to FDA requirements at all your sites,” FDA stated.

Source: FDA

Recent Videos
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content